Prosecution Insights
Last updated: April 19, 2026
Application No. 18/034,136

TRUNCATED MODIFIED RECOMBINANT ADAMTS13 AND USES THEREOF

Non-Final OA §102
Filed
Apr 27, 2023
Examiner
DAVIS, RUTH A
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The United States Department of Health and Human Services
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
3y 4m
To Grant
92%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allow Rate
540 granted / 889 resolved
+0.7% vs TC avg
Strong +31% interview lift
Without
With
+30.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
45 currently pending
Career history
934
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
33.3%
-6.7% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
30.3%
-9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 889 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of Group I, claims 1 – 5, 7 – 10, 14 and 16 in the reply filed on August 18, 20025 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 1 – 5, 7 – 10, 14, 16, 19, 22, 36 – 38, 43, 52, 54 – 55 are pending; claims 19, 22, 36 – 38, 43, 52 and 54 – 55 are withdrawn; claims 1 – 5, 7 – 10, 14 and 16 have been considered on the merits. Information Disclosure Statement The information disclosure statement (IDS) submitted on November 7, 2023 and August 18, 2025 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. Specification The disclosure is objected to because of the following informalities: On pages 2, 5 and 6, “mrADAMST13” is spelled incorrectly. Appropriate correction is required. Claim Objections Claim 1 is objected to because of the following informalities: “mrADAMST13” is spelled incorrectly. Appropriate correction is required. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1 – 3, 9 – 10, 14 and 16 are rejected under 35 U.S.C. 102a1 and 102a2 as being anticipated by Bare et al. (US 2012/0108651) OR Bancel et al. (US 8999380). Regarding claims 1 – 3, Bare teaches a polypeptide comprising at least 95% of SEQ ID NO:7 (search result 8, SEQ ID 125, 95.1% match); while Bancel teaches a polypeptide comprising at least 95% of SEQ ID NO:7 (search result 1, SEQ ID 780, 95.1% match). These sequences match at least 90%, 92% and 95% and are not SEQ ID NO:5 as disclosed by the specification. Regarding claims 9 – 10, 14 and 16, Bare teaches the polypeptide is recombinant, nucleic acids encoding the polypeptide, vectors comprising the nucleic acid and cells comprising the polypeptide (0039, 0043, p.15); while Bancel teaches the polypeptide is recombinant, nucleic acids encoding the polypeptide, vectors comprising the nucleic acid and cells comprising the polypeptide (col.13 – 14). The references anticipate the claimed subject matter. Allowable Subject Matter Claims 4 – 5 and 7 – 8 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RUTH A DAVIS whose telephone number is (571)272-0915. The examiner can normally be reached Monday - Friday (8am - 4pm). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RUTH A DAVIS/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Apr 27, 2023
Application Filed
Oct 31, 2025
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599140
Agricultural compositions and methods for the delivery of plant health-promoting microbes
2y 5m to grant Granted Apr 14, 2026
Patent 12589125
YOGURT FOR REGULATING INTESTINAL TRACT, PREPARATION METHOD THEREFOR, AND USE THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12584095
EXTRACELLULAR VESICLES FROM MICROALGAE
2y 5m to grant Granted Mar 24, 2026
Patent 12571790
BIOENERGETIC PROFILING OF CIRCULATING BLOOD CELLS AND SYSTEMS, DEVICES, AND METHODS RELATING THERETO
2y 5m to grant Granted Mar 10, 2026
Patent 12569462
Animal Feeds and Feed Premixes Containing Betaine and a Phytase
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
92%
With Interview (+30.9%)
3y 4m
Median Time to Grant
Low
PTA Risk
Based on 889 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month